Vanguard Group Inc Halozyme Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 12,245,602 shares of HALO stock, worth $787 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,245,602
Previous 12,831,503
4.57%
Holding current value
$787 Million
Previous $819 Million
22.2%
% of portfolio
0.01%
Previous 0.02%
Shares
17 transactions
Others Institutions Holding HALO
# of Institutions
600Shares Held
127MCall Options Held
372KPut Options Held
328K-
Black Rock Inc. New York, NY17.6MShares$1.13 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.94MShares$381 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$223 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$218 Million3.92% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA2.54MShares$163 Million0.1% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.95B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...